{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "HTS",
      "cardiomyocyte",
      "disease modeling",
      "drug attrition",
      "drug discovery",
      "heart disease",
      "hiPSC",
      "screen"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33740432",
  "DateCompleted": {
    "Year": "2021",
    "Month": "09",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "11"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.chembiol.2021.02.016",
      "S2451-9456(21)00101-X"
    ],
    "Journal": {
      "ISSN": "2451-9448",
      "JournalIssue": {
        "Volume": "28",
        "Issue": "3",
        "PubDate": {
          "Year": "2021",
          "Month": "Mar",
          "Day": "18"
        }
      },
      "Title": "Cell chemical biology",
      "ISOAbbreviation": "Cell Chem Biol"
    },
    "ArticleTitle": "Human iPSC modeling of heart disease for drug development.",
    "Pagination": {
      "StartPage": "271",
      "EndPage": "282",
      "MedlinePgn": "271-282"
    },
    "Abstract": {
      "AbstractText": [
        "Human induced pluripotent stem cells (hiPSCs) have emerged as a promising platform for pharmacogenomics and drug development. In cardiology, they make it possible to produce unlimited numbers of patient-specific\u00a0human cells that reproduce hallmark features of heart disease in the culture dish. Their potential applications include the discovery of mechanism-specific therapeutics, the evaluation of safety and efficacy in a human context before a drug candidate reaches patients, and the stratification of patients for clinical trials. Although this new technology has the potential to revolutionize drug discovery, translational hurdles have hindered its widespread adoption for pharmaceutical development. Here we discuss recent progress in overcoming these hurdles that should facilitate the use of hiPSCs to develop new medicines and individualize therapies for heart disease."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021 Elsevier Ltd. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Stanford Cardiovascular Institute, 240 Pasteur Drive, Biomedical Innovation Building, Palo Alto, CA 94305, USA; Department of Medicine, Stanford University, Stanford, CA 94305, USA."
          }
        ],
        "LastName": "Hnatiuk",
        "ForeName": "Anna P",
        "Initials": "AP"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Stanford Cardiovascular Institute, 240 Pasteur Drive, Biomedical Innovation Building, Palo Alto, CA 94305, USA; Department of Medicine, Stanford University, Stanford, CA 94305, USA."
          }
        ],
        "LastName": "Briganti",
        "ForeName": "Francesca",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Stanford Cardiovascular Institute, 240 Pasteur Drive, Biomedical Innovation Building, Palo Alto, CA 94305, USA; Department of Pediatrics, Stanford University, Stanford, CA 94305, USA."
          }
        ],
        "LastName": "Staudt",
        "ForeName": "David W",
        "Initials": "DW"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Stanford Cardiovascular Institute, 240 Pasteur Drive, Biomedical Innovation Building, Palo Alto, CA 94305, USA; Department of Medicine, Stanford University, Stanford, CA 94305, USA. Electronic address: mmercola@stanford.edu."
          }
        ],
        "LastName": "Mercola",
        "ForeName": "Mark",
        "Initials": "M"
      }
    ],
    "GrantList": [
      {
        "GrantID": "P01 HL141084",
        "Acronym": "HL",
        "Agency": "NHLBI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 HL130840",
        "Acronym": "HL",
        "Agency": "NHLBI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 HL138539",
        "Acronym": "HL",
        "Agency": "NHLBI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "T32 HL094274",
        "Acronym": "HL",
        "Agency": "NHLBI NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Cell Chem Biol",
    "NlmUniqueID": "101676030",
    "ISSNLinking": "2451-9448"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cardiovascular Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "chemical synthesis",
        "chemistry",
        "pharmacology"
      ],
      "DescriptorName": "Cardiovascular Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Development"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Heart Diseases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Induced Pluripotent Stem Cells"
    }
  ],
  "CoiStatement": "Declaration of interests M.M. has equity in Vala Sciences, Inc., and is on its scientific advisory board. The authors declare no other competing interests."
}